Immix Biopharma - Reaffirmed long-term focus on outpatient CAR-T
⬆ $Immix Biopharma Inc(IMMX)$ - Immix Biopharma is continuing its strategic pivot towards exploring non-traditional indications for its CAR-T asset, NXC-201, leading with... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/immix-biopharma-reaffirmed-long-term-focus-on-outpatient-car-t?utm_source=tiger_community By Edison Investment Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/edison-investment-research?utm_source=tiger_community On Immix Biopharma Inc (IMMX):- https://www.smartkarma.com/entities/immix-biopharma-inc?utm_source=tiger_community
Immix Biopharma - Marching towards US clinical trials for NXC-201
⬆ $Immix Biopharma Inc(IMMX)$ - Immix Biopharma is closer to dosing its first US patient for lead CAR-T asset NXC-201, with the appointment of the Memorial Sloan Kettering Cancer... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/immix-biopharma-marching-towards-us-clinical-trials-for-nxc-201?utm_source=tiger_community By Edison Investment Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/edison-investment-research?utm_source=tiger_community On Immix Biopharma Inc (IMMX):- https://www.smartkarma.com/entities/immix-biopharma-inc?utm_source=tiger_community
Immix Biopharma - 2023 recap with a preview of active year ahead
⬆ $Immix Biopharma Inc(IMMX)$ - IMMX has shared a 12-month recap, capturing key clinical and regulatory events from 2023, setting the stage for an active 2024. Its lead CAR-T... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/immix-biopharma-2023-recap-with-a-preview-of-active-year-ahead?utm_source=tiger_community By Edison Investment Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/edison-investment-research?utm_source=tiger_community On Immix Biopharma Inc (IMMX):- https://www.smartkarma.com/entities/immix-biopharma-inc?utm_source=tiger_community
Immix Biopharma - Updates galore: NXC-201 ODD (EU) and raise
⬆ $Immix Biopharma Inc(IMMX)$ - Immix Biopharma has released back-to-back updates, including EU orphan drug designation (ODD) for its lead CAR-T asset NXC-201, addressing amyloid... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/immix-biopharma-updates-galore-nxc-201-odd-eu-and-raise?utm_source=tiger_community By Edison Investment Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/edison-investment-research?utm_source=tiger_community On Immix Biopharma Inc (IMMX):- https://www.smartkarma.com/entities/immix-biopharma-inc?utm_source=tiger_community
Immix Biopharma - Increased legroom following common-only raise
⬆ $Immix Biopharma Inc(IMMX)$ - Immix Biopharma has announced a $15m (gross), fully underwritten equity issue. The company will use the proceeds to fund clinical trials for lead... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/immix-biopharma-increased-legroom-following-common-only-raise?utm_source=tiger_community By Edison Investment Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/edison-investment-research?utm_source=tiger_community On Immix Biopharma Inc (IMMX):- https://www.smartkarma.com/entities/immix-biopharma-inc?utm_source=tiger_community
Immix Biopharma - Encouraging stream of ALA data newsflow
⬆ $Immix Biopharma Inc(IMMX)$ - Immix presented encouraging new data at the American Society of Hematology (ASH) 2023 meeting for its Nexcella subsidiary’s lead CAR-T asset,... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/immix-biopharma-encouraging-stream-of-ala-data-newsflow?utm_source=tiger_community By Edison Investment Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/edison-investment-research?utm_source=tiger_community On Immix Biopharma Inc (IMMX):- https://www.smartkarma.com/entities/immix-biopharma-inc?utm_source=tiger_community
Immix Biopharma - CAR-T trial moves to US with outpatient potential
⬆ $Immix Biopharma Inc(IMMX)$ - The FDA has accepted Immix’s Investigational New Drug (IND) application for lead CAR-T asset NXC-201. In our view, this decision from the FDA... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/immix-biopharma-car-t-trial-moves-to-us-with-outpatient-potential?utm_source=tiger_community By Edison Investment Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/edison-investment-research?utm_source=tiger_community On Immix Biopharma Inc (IMMX):- https://www.smartkarma.com/entities/immix-biopharma-inc?utm_source=tiger_community
Immix Biopharma - A quarter of progress for both lead assets
⬆ $Immix Biopharma Inc(IMMX)$ - Throughout Q323, Immix shared encouraging updates for the clinical development of lead CAR-T asset NXC-201, including the announcement of orphan... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/immix-biopharma-a-quarter-of-progress-for-both-lead-assets?utm_source=tiger_community By Edison Investment Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/edison-investment-research?utm_source=tiger_community On Immix Biopharma Inc (IMMX):- https://www.smartkarma.com/entities/immix-biopharma-inc?utm_source=tiger_community
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.